ArticleCurrent infectious disease reports2010
Drug-Resistant Malaria: The Era of ACT.
Article in Current infectious disease reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis.BMC infectious diseases · 2018Pooled it
- How do malaria testing and treatment subsidies affect drug shop client expenditures? A cross-sectional analysis in Western Kenya.BMJ open · 2022Trial
- Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial.Malaria journal · 2018Trial
- Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.The Lancet. Infectious diseases · 2016Trial
- Trial
- Trial
- Efficacy of artemether-lumefantrine combination for the treatment of uncomplicated Plasmodium falciparum malaria after 16 years of its introduction into Ghana's antimalarial medicines policy.Malaria journal · 2026Article
- A review of natural products as a source of next-generation drugs against apicomplexan parasites.npj antimicrobials and resistance · 2025Review
- High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing.The Journal of infectious diseases · 2025Article
- High frequency of artemisinin partial resistance mutations in the great lake region revealed through rapid pooled deep sequencing.medRxiv : the preprint server for health sciences · 2024Article
- Evaluation of the binding interactions between Plasmodium falciparum Kelch-13 mutant recombinant proteins with artemisinin.PloS one · 2024Article
- Article
- Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- coiaf: Directly estimating complexity of infection with allele frequencies.PLoS computational biology · 2023Article
- Achieving malaria testing and treatment targets for children under five in Mozambique: a cost-effectiveness analysis.Malaria journal · 2022Article
- Experience and confidence in health technologies: evidence from malaria testing and treatment in Western Kenya.BMC public health · 2022Article
- Using an antimalarial in mosquitoes overcomes Anopheles and Plasmodium resistance to malaria control strategies.PLoS pathogens · 2022Article
- Low Complexity of Infection Is Associated With Molecular Persistence ofFrontiers in epidemiology · 2022Article
- Methodological approaches for analysing data from therapeutic efficacy studies.Malaria journal · 2021Article
- Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy.Malaria journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
As drug-resistant falciparum malaria has continued to evolve and spread worldwide, artemisinin-based combination therapies (ACT) have become the centerpiece of global malaria control over the past decade. This review discusses how advances in antimalarial drug resistance monitoring and rational use of the array of ACTs now available can maximize the impact of this highly efficacious therapy, even as resistance to artemisinins is emerging in Southeast Asia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.